Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 31, 2022 - Issue 6: Breast Cancer
Submit an article Journal homepage
7,055
Views
13
CrossRef citations to date
0
Altmetric
Editorial

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Alessandro RizzoStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyCorrespondence[email protected]
View further author information
,
Antonio CusmaiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information
,
Silvana AcquafreddaStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information
,
Lucia RinaldiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information
&
Gennaro PalmiottiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information
Pages 495-498 | Received 23 Dec 2021, Accepted 10 Feb 2022, Published online: 17 Feb 2022

References

  • Zangardi ML, Spring LM, and Nagayama A, et al. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy? Expert Opin Investig Drugs. 2019Feb;28(2):107–112. Epub 2018 Dec 17. PMID: 30507322.
  • Nagayama A, Vidula N, Ellisen L, et al. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020May11;12:1758835920915980. PMID: 32426047; PMCID: PMC7222243.
  • Abbas AJ, Ibrahim MF, Saifo MS. Antibody-Drug Conjugates Used in Breast Cancers. J Oncol. 2021 Jun 24; 2021:9927433. https://doi.org/10.1155/2021/9927433. PMID: 34257655; PMCID: PMC8257388.
  • Cipriano É, Mesquita A. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl). 2021Mar22;15:11782234211002491. PMID: 33814914; PMCID: PMC7989121.
  • Nagayama A, Vidula N, Bardia A. Novel Therapies for Metastatic Triple-Negative Breast Cancer: spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology (Williston Park). 2021May13;35(5):249–254. PMID: 33983696.
  • Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021Jun;18(6):327–344. Epub 2021 Feb 8. PMID: 33558752; PMCID: PMC8287784.
  • Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021Aug11;23(1):84. PMID: 34380530; PMCID: PMC8356386.
  • Nandini D, Jennifer A, Pradip D. Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: from Negative to Positive. Pharmaceuticals (Basel). 2021May12;14(5):455. PMID: 34065837; PMCID: PMC8150754.
  • Modi S, Pusztai L, Forero A, et al. Abstract PD3-14: phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res. 2018;78: PD3-14-PD13-14.
  • Tsai M, Han HS, Montero AJ, et al. Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Ann Oncol. 2021;32:S474–475.
  • Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015Sep;125(9):3335–3337. Epub 2015 Sep 1. PMID: 26325031; PMCID: PMC4588312.
  • Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2021 Jun;30:1–8. Epub ahead of print. PMID: 34167433
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
  • Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: mechanism, Combinations, and Clinical Outcome. Front Pharmacol. 2017;8:561.
  • McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2021Jul;21(7):903–913. Epub 2020 Dec 27. PMID: 33089726.
  • Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019Aug2;8:F1000 Faculty Rev–1342. PMID: 31448088; PMCID: PMC6681627.
  • Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020Jun9;22(1):61. PMID: 32517735; PMCID: PMC7285581.
  • Cao AT, Higgins S, Stevens N, et al. Abstract 2742: additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Res. 2018;78:2742.
  • Lee KA, Shaw HM, Bataille V, et al. Role of the gut microbiome for cancer patients receiving immunotherapy: dietary and treatment implications. Eur J Cancer. 2020Oct; 138: 149–155 Epub 2020 Sep 2. PMID: 32889369
  • Ma R, Yi B, Riker AI, et al. Metformin and cancer immunity. Acta Pharmacol Sin. 2020Nov;41(11):1403–1409. Epub 2020 Aug 31. PMID: 32868904; PMCID: PMC7656961.
  • Pondé N, Aftimos P, Piccart M. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. Curr Treat Options Oncol. 2019Apr1;20(5):37. PMID: 30931493.
  • Bianchini G, Balko JM, and Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016Nov;13(11):674–690. Epub 2016 May 17. PMID: 27184417; PMCID: PMC5461122.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.